Your Source for Venture Capital and Private Equity Financings

A-Alpha Bio Secures $22.4M Series A2 Round

SEATTLE, WA, A-Alpha Bio, a synthetic biology and machine learning (ML) company that measures and engineers protein-protein interactions, today announced a $22.4 million Series A2.
The round was led by previous investor Perceptive Xontogeny Ventures, with strong support from Madrona and other existing investors. Breakout Ventures joined the round as a new investor, and Lindy Fishburne, Managing Partner at Breakout Ventures, will join the board as an observer.

The Series A2 brings A-Alpha's total funding to $51M, including non-dilutive funding from The Bill & Melinda Gates Foundation, the National Science Foundation, and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions. The company's AlphaSeq platform applies synthetic biology to experimentally measure millions of protein-protein interaction affinities simultaneously. Protein binding data is incorporated into the company's AlphaBind platform to train machine learning models that predict binding from sequence. A-Alpha Bio uses both platforms to discover and optimize high-impact therapeutics for their own pipeline and in partnership with industry leaders.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors